These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 836242)

  • 21. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia.
    Al-Samkari H; Kritharis A; Rodriguez-Lopez JM; Kuter DJ
    J Intern Med; 2019 Feb; 285(2):223-231. PubMed ID: 30191646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization.
    Trojanowski P; Jargiello T; Trojanowska A; Klatka J
    Acta Radiol; 2011 Oct; 52(8):846-9. PubMed ID: 21816895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enovid therapy (norethynodrel with mestranol) for fibrocystic disease.
    Ariel IM
    Am J Obstet Gynecol; 1973 Oct; 117(4):453-9. PubMed ID: 4743352
    [No Abstract]   [Full Text] [Related]  

  • 24. Hormone therapy for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
    McGee RR
    South Med J; 1995 Oct; 88(10):1086. PubMed ID: 7481972
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.
    Geisthoff UW; Seyfert UT; Kübler M; Bieg B; Plinkert PK; König J
    Thromb Res; 2014 Sep; 134(3):565-71. PubMed ID: 25005464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): clinical manifestations and multidisciplinary management].
    Frigerio C; Aebischer N; Baud D; Bonafe L; Fellmanne F; Ikonomidis C; Mazzolai L; Michel P; Nichita C; Qanadli SD; Lazor R
    Rev Med Suisse; 2016 May; 12(517):896-901. PubMed ID: 27323484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Epistaxis in Rendu-Osler-Weber disease treated with selective embolization--case report].
    Jarzabek M; Trojanowski P; Szajner M; Pyra K; Sojka M; Szczerbo-Trojanowska M
    Przegl Lek; 2012; 69(7):317-9. PubMed ID: 23276024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life.
    Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM
    Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal closure for the treatment of epistaxis secondary to hereditary hemorrhagic telangiectasia.
    Sena Esteves S; Cardoso C; Silva A; Abrunhosa J; Almeida E Sousa C
    Acta Otorrinolaringol Esp; 2016; 67(6):345-348. PubMed ID: 27079134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External beam radiotherapy for severe epistaxis from Osler-Weber-Rendu disease.
    Harwood AR; Wojak JC; Barry R
    J La State Med Soc; 2002; 154(3):154-5. PubMed ID: 12139363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free-flap reconstruction for the management of life-threatening hereditary hemorrhagic telangiectasia.
    Choi JW; Joo YH; Jeong WS; Jang YJ
    Auris Nasus Larynx; 2017 Oct; 44(5):607-611. PubMed ID: 27616747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Hereditary Hemorrhagic Telangiectasia-Related Epistaxis.
    Sautter NB; Smith TL
    Otolaryngol Clin North Am; 2016 Jun; 49(3):639-54. PubMed ID: 27267016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Rendu-Osler-Weber disease].
    Sys L; van den Hoogen FJ
    Ned Tijdschr Tandheelkd; 2005 Sep; 112(9):336-9. PubMed ID: 16184912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
    Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.
    Yaniv E; Preis M; Hadar T; Shvero J; Haddad M
    Laryngoscope; 2009 Feb; 119(2):284-8. PubMed ID: 19160429
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study.
    Dheyauldeen S; Abdelnoor M; Bachmann-Harildstad G
    Am J Rhinol Allergy; 2011; 25(4):214-8. PubMed ID: 21819756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rendu-Osler-Weber disease: experience with 56 patients.
    Sabbà C; Pasculli G; Cirulli A; Gallitelli M; Virgilio G; Guastamacchia E; Resta F; Palasciano G
    Ann Ital Med Int; 2002; 17(3):173-9. PubMed ID: 12402665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin D levels are associated with epistaxis severity and bleeding duration in hereditary hemorrhagic telangiectasia.
    Weber LM; McDonald J; Whitehead K
    Biomark Med; 2018 Apr; 12(4):365-371. PubMed ID: 29537299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia.
    Minami K; Haji T
    Acta Otolaryngol; 2016; 136(5):528-31. PubMed ID: 26808464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of epistaxis on health-related quality of life in patients with hereditary hemorrhagic telangiectasia.
    Merlo CA; Yin LX; Hoag JB; Mitchell SE; Reh DD
    Int Forum Allergy Rhinol; 2014 Nov; 4(11):921-5. PubMed ID: 25145809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.